AMLo is immensely proud to announce the poster publication of the AMBLor® validation cohort at the recent Society of Melanoma Research Congress 2021:
Validation of AMBLor as a prognostic biomarker for non-ulcerated cutaneous AJCC stage I/II melanomas
Dr Tom Ewen from Professor Penny Lovat’s team at Newcastle University gave a video presentation. He showed how AMBRA1 and/or loricrin retention in the skin overlying melanoma, in a cohort of 411 Stage I and II patients, predicted low risk of metastases with an NPV of 97.14%. This means that patients with an AMBLor “proteins maintained” result could be relieved of some of the anxiety and burden of investigations such as sentinel lymph node biopsy and intensive follow-up regimens.
Conversely the AMBLor test’s low PPV and assay specificity means that it is not a suitable test to predict high risk melanoma and instead patients should be maintained on their current at-risk standard of care and follow-up. In such cases the surgical removal of the primary melanoma may be a curative event.
Click here to read more about the AMBLor test. To download a PDF of the poster, click the image below.
2021/AMBLor/UK/0024
November 2021
